Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4110367)

Published in Prz Gastroenterol on June 26, 2014

Authors

Mustafa Celik1, Mahmut Arabul1, Cem Cekiç1, Sezgin Vatansever1, Serkan Ipek1, Fatih Aslan1, Belkıs Unsal1

Author Affiliations

1: Department of Gastroenterology, Atatürk Training and Research Hospital, Izmir, Turkey.

Articles cited by this

EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14

A "NEW" ANTIGEN IN LEUKEMIA SERA. JAMA (1965) 6.21

Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (2009) 2.97

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol (2010) 2.61

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58

Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology (2010) 2.47

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol (2007) 1.85

A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology (2010) 1.58

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol (2009) 1.25

Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther (2007) 1.20

A new role for an old marker, HBsAg. J Hepatol (2010) 1.12

A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther (2009) 1.01

Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther (2007) 0.99

Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol (2009) 0.93

Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J Viral Hepat (2011) 0.83